Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14.00 to 16:00.
Biovica is nearing market launch of DiviTum[®] in the US for the monitoring of metastatic breast cancer treatments. DiviTum[®] is already being sold for research purposes, primarily to major pharmaceutical companies for use in clinical studies. After an FDA approval, the large market for patient monitoring will become available.
We therefore invite you to a virtual Capital Markets Day on 11 May 2020 at 2:00 to 4:00 pm.
Link will be found at Biovicas website: www.biovica.com/biovica/investor-relations/events/ questions can be sent to email@example.com
At the Capital Markets Day Robert Dann, SVP Marketing and US Business and Henrik Winther SVP Business Development, will present the plan for the market launch of DiviTum[®], oncologist Samuel Rotstein from Karolinska Hospital will present his views on the value DiviTum[®] could bring patients and the healthcare system, and CEO Anders Rylander will give an update on Biovica's current situation.
This information was distributed by Cision http://www.cisionwire.se/